Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, announces it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. Previse’s mission is to save lives and improve patient health through prevention and early detection. Previse leverages groundbreaking biomarker technology developed by Stephen Meltzer, M.D., and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine and exclusively licensed to Previse.
Read the full article: Castle Biosciences to Acquire Previse //
Source: https://www.globenewswire.com/news-release/2025/05/05/3074519/0/en/Castle-Biosciences-to-Acquire-Previse.html